Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

• Candel Therapeutics investor presentation highlighted positive phase 3 data for lead candidate aglatimagene besadenovec (CAN-2409) in localized, intermediate- to high-risk prostate cancer, with trial meeting primary endpoint of disease-free survival.
• Program also cited positive overall survival signals from randomized phase 2a studies in borderline resectable pancreatic cancer, with additional phase 2a overall survival data in therapy-resistant non-small cell lung cancer.
• Regulatory status includes FDA RMAT designation in prostate cancer, Fast Track designations in prostate, NSCLC, pancreatic cancer, with Orphan Drug designation in pancreatic cancer.
• Balance sheet snapshot showed cash and cash equivalents of $194.8 million as of March 31, 2026, with expected runway into Q1 2028.
• Financing updates included term loan facility with Trinity Capital of up to $130 million, with $100 million royalty funding agreement with RTW Investments tied to approval of aglatimagene in localized prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on May 14, 2026, and is solely responsible for the information contained therein.